TRT costs on TikTok: what creators leave out of the price tag

What did @harleymeds.com actually say?

The creator claims that $169 per month is a reasonable price for TRT and that anyone paying more than $200 is "getting ripped off." That's a bold, sweeping statement aimed directly at patients who may be using traditional urology practices, endocrinologists, or other telehealth platforms. The $169 figure supposedly covers testosterone medication, physician visits, ongoing lab work, injection supplies, and home delivery. On its face, that's a lot of services bundled into one price point.

Worth noting: the video ends with a referral solicitation. The creator asks viewers to comment "TRT" to receive clinic information. That's an affiliate or referral dynamic, which doesn't automatically make the information wrong, but it does mean the creator has a financial interest in the recommendation. That context matters when evaluating the "you're getting ripped off" framing.

Does the science back this up?

There's no peer-reviewed research that establishes a "correct" monthly price for TRT, so the $200 threshold is an opinion, not a clinical benchmark. What the research does tell us is that TRT pricing varies enormously based on formulation, monitoring protocol, and practice setting.

A 2021 analysis published in the Journal of Urology (Patel et al., 2021) found that out-of-pocket costs for testosterone therapy in the United States ranged from under $50 to over $500 per month depending on delivery method and insurance status. Injectable testosterone cypionate is consistently the cheapest formulation when purchased at retail pharmacies, sometimes under $30 per month for the drug alone. Gels, patches, and pellets cost significantly more. GoodRx pricing data confirms that a 10mL vial of testosterone cypionate can cost between $25 and $80 without insurance at major pharmacy chains.

The point is: the drug itself is cheap. What varies is the clinical infrastructure around it, which is exactly what bundled telehealth models are pricing. Whether that bundle is worth it depends on what monitoring those physician visits actually include.

What did they get wrong (or right)?

They got the general pricing ballpark roughly right for a bundled telehealth model. Competitors in the direct-to-patient TRT telehealth space, including well-known platforms, price all-inclusive monthly programs between $99 and $250. So $169 is not unusual. Calling anything over $200 a "rip-off" is an overstatement, but it's not fabricated from thin air.

Where this gets slippery is the claim that the bundle includes "all of your continuing blood work." That deserves scrutiny. Adequate TRT monitoring requires checking total testosterone, free testosterone, estradiol, hematocrit, and PSA at minimum. Some platforms offer a limited panel and call it sufficient. The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommend hematocrit monitoring every 3 to 6 months in the first year. If the $169 bundle covers a genuinely complete panel at appropriate intervals, it's a solid value. If it covers a stripped-down panel, "all your blood work" is marketing language, not a clinical commitment.

The referral mechanic at the end is also worth flagging. Recommending a specific clinic via DM without disclosing a financial relationship is an FTC disclosure issue, not just a personal transparency one.

What should you actually know?

TRT pricing is legitimately confusing, and the creator is right that patients often overpay when they don't know what to compare. But the $200 cutoff is arbitrary. A patient seeing an endocrinologist with insurance coverage might pay less out of pocket. A patient on a testosterone gel formulation will almost certainly pay more, often for legitimate clinical reasons.

Before committing to any bundled TRT program, patients should ask specific questions: What labs are included and how often? What is the prescriber's licensure? Is the testosterone compounded or FDA-approved? Compounded testosterone is not equivalent to FDA-approved formulations, and the FDA has issued warnings about quality control at some compounding pharmacies (FDA, 2019). The two should not be treated as interchangeable.

The Endocrine Society guidelines also note that TRT is indicated for men with documented hypogonadism, not simply low-normal testosterone. Any program that skips a thorough baseline evaluation in the name of convenience is cutting corners on patient safety, regardless of price.